Nanoantibody against herpes simplex virus-1, herpes simplex virus-2 and varicella-zoster virus in the central nervous system

A modified nanoantibody, NbHSV69B-TfRL, addresses the limitations of existing HSV and VZV treatments by crossing the blood-brain barrier and effectively neutralizing these viruses, offering a new diagnostic and therapeutic approach.

WO2026239040A1PCT designated stage Publication Date: 2026-11-19SERVICIO ANDALUZ DE SALUD (SAS) +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/ES2026/070268
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current treatments for herpes simplex virus (HSV) and varicella-zoster virus infections, such as acyclovir, do not cure the infection and are limited by the blood-brain barrier, leading to challenges in treating central nervous system infections and requiring new, effective alternatives.

Method used

Development of a nanoantibody, NbHSV69B-TfRL, which is modified to include a transferrin receptor ligand (TfRL) sequence, allowing it to cross the blood-brain barrier and neutralize HSV-1, HSV-2, and VZV by binding to the gB glycoprotein, thereby inhibiting viral infection.

Benefits of technology

The nanoantibody effectively neutralizes HSV-1, HSV-2, and VZV infections, including those in the central nervous system, with enhanced efficacy compared to existing drugs and the ability to diagnose infections through immunofluorescence assays.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000034_0000
    Figure 00000034_0000
  • Figure 00000034_0001
    Figure 00000034_0001
  • Figure 00000035_0000
    Figure 00000035_0000
Patent Text Reader

Abstract

The present invention relates to a specific nanoantibody specifically against the human alpha-herpesviruses Herpes simplex virus-1, Herpes simplex virus-2 and Varicella-zoster virus, and its use in both the diagnosis and treatment of the infection caused by these viruses, locally and in the central nervous system, due to its ability to cross the blood-brain barrier. The invention also relates to the method for producing the nanoantibody.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] Nanoantibody against Herpes Simplex 1 virus, Herpes Simplex 2 and Varicella Zoster virus, at the level of the Central Nervous System.

[0003] TECHNICAL FIELD OF INVENTION

[0004] The present invention falls within the fields of medicine, immunology, biotechnology, and virology, and more specifically, relates to the diagnosis and treatment of infectious diseases transmitted by viruses using immunological techniques. Specifically, it describes a specific nanoantibody against Herpes Simplex virus type 1 and type 2, and Varicella Zoster virus, for use in both the diagnosis and treatment of infection caused by these viruses locally and in the brain parenchyma.

[0005] PRIOR ART

[0006] The herpes simplex virus (HSV) is the cause of one of the most common infections worldwide. It is divided into two types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). HSV-1 is primarily transmitted through oral contact and causes oral and labial herpes, and less frequently, genital herpes. HSV-2 is transmitted through sexual contact, causes genital herpes, and, to a lesser extent, orolabial herpes. Both oral and genital herpes are mostly asymptomatic, but can cause painful blisters or sores. The infection is lifelong due to its ability to remain dormant in the central nervous system (CNS), and symptoms can reappear after many years. The varicella-zoster virus (VZV) is the third virus in the human alpha-herpesvirus subfamily, along with the two herpes simplex viruses mentioned above.Primary infection with the VZV virus causes chickenpox, after which the virus remains latent in the CNS and its reactivation, due to various factors, produces shingles or herpes zoster, mainly in elderly or immunocompromised patients.

[0007] According to the latest data, an estimated 67% of the world's population is infected with HSV-1, and many of these infections are acquired during childhood through orolabial mucosa, while HSV-2 infections occur later, usually through sexual transmission, with a global prevalence of 13%. Furthermore, it is estimated that in the United States alone, this number will increase by more than 600,000 new infections per year by 2050.

[0008] HSV-1 infection can lead to complications in immunocompromised individuals, where the virus can cause more severe symptoms and viral reactivation is more frequent. Furthermore, in some cases, infection with these viruses can even cause serious problems such as encephalitis, meningitis, or postherpetic neuralgia.

[0009] These three viruses—human herpes simplex virus type 1, human herpes simplex virus type 2, and varicella-zoster virus—belong to the family Orthoerpesviridae and the subfamily Alphaherpesvirus. They consist of a core containing linear, double-stranded DNA. This genome is encapsulated within an icosahedral capsid, or nucleocapsid, which is surrounded by a protein coat called the tegument, involved in viral replication within the host cell.

[0010] The outermost envelope contains four crucial membrane proteins: the trimeric glycoprotein B (gB), the receptor-binding glycoproteins C and D (gC and gD), and the gH / gL heterodimer. These proteins mediate entry into the host cell through interaction with its surface proteins. Unlike other viruses, herpesviruses encode receptor-binding and membrane fusion functions using different proteins. gB is a trimeric transmembrane protein with five extracellular domains. It is the viral fusion protein responsible for insertion into the host cell membrane and the driving force behind the fusion of the viral envelope and the cell membrane.

[0011] Human alpha-herpesvirus infection has two main stages: first, the virus binds to the cell surface, and second, it fuses with the plasma membrane. Binding to the cell surface occurs through specific cell receptors on the viral envelope, such as gB and gC, which bind to the cell surface proteoglycan heparan sulfate. GD, on the other hand, binds specifically to at least one of three known entry receptors: herpesvirus entry mediator (HVEM), nectin-1, or heparan sulfate 3-0. The subsequent stage of fusion of the viral envelope with the cell's plasma membrane involves the glycoproteins gB, gD, gH, and gL.

[0012] Therefore, it can be said that the complex formed by the gD dimer, the gH / gL heterodimer, and the gB trimer are necessary and sufficient for the entry of the virus into the cell. The binding of gD to the entry receptor displaces the carboxy-terminal end of the gD ectodomain and transmits a signal to the gH / gL complex, which in turn activates the gB fusion protein to insert hydrophobic fusion loops into the cell membrane [1, 2].

[0013] Currently, there are various treatments that help reduce the severity and frequency of symptoms caused by human alpha-herpesviruses, but these treatments do not cure the infection, so people who are infected with these viruses are forced to adapt to living with the infection.

[0014] The main drugs used are the antivirals acyclovir (ACV) (the drug of choice), famciclovir, and valacyclovir. All of these belong to the group of nucleoside analogs. These analogs are an important class of antiviral agents frequently used against infections caused by various viruses, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and herpes simplex virus (HSV). Nucleoside analogs are involved in DNA replication and are used by viral polymerases, but not by human polymerases. ACV is phosphorylated intracellularly by viral kinases, and the resulting triphosphate competes with guanosine for incorporation into viral DNA, blocking the activity of viral DNA polymerase. The use of ACV to treat infections caused by herpes simplex virus was approved in 1982. It can be administered topically or systemically.The recommended oral dose is 200 to 800 mg three to five times a day for 5 to 10 days, and the typical intravenous dose for severe infections is 5 to 10 mg / kg every 8 hours for 5 to 10 days. One of the adverse effects of ACV is neurotoxicity. This is caused by the high intravenous administration indicated for the treatment of encephalitis.

[0015] The World Health Organization currently has programs in place to raise awareness about herpes virus infections, including HSV-1, HSV-2, and VZV, and to improve access to antiviral medications. It also supports research to develop new infection prevention and control strategies, demonstrating the importance and necessity of new alternatives to existing treatments.

[0016] Antibodies, or immunoglobulins, are molecules composed of two heavy chains (H) and two light chains (L). In 1993, Professor Raymond Hamers published that species of the Camelidae family contained a fraction of functional antibodies composed solely of heavy chains (Heavy Chain Antibodies or “HcAbs”). These HcAbs are homodimers where each monomer has an antigen-binding fragment (Fab fragment) reduced to a single variable domain (VHH or nanobody). These antibody fragments, derived from HcAbs, are also called single-chain antibodies, nanobodies, single-domain antibodies, VHH antibodies, or simply “nanobodies.” In this dissertation, we will refer to them as nanobodies.

[0017] The H chain of nanobodies is composed of three globular domains: the VHH, a hinge region, and two Fe constant domains (CH2 and CH3). These Fe domains are highly homologous to the Fe domains of conventional antibodies. The organization of the variable domain of the H chain of the conventional antibody (VH domain) and the VHH domain is similar: both are composed of four conserved sequences, the frame regions (FRs), flanking three hypervariable regions (HVs) or complementarity-determining regions (CDRs).

[0018] However, there are some clear differences in the alignment of the amino acid sequences of the VH and VHH domains: the CDR1 and CDR3 regions of VHH are larger than those of VH; the VHH sequence carries significant substitutions of highly conserved amino acids located in the frame-2 (FR2) region; the hydrophobic residues Val42, Gly49, Leu50, and Trp52 in the VH of conventional antibodies are replaced in the VHH of single-stranded antibodies by the hydrophilic residues Phe / Tyr42, Glu49, Arg / Cys50, and Leu / Gly52. The presence of more hydrophilic amino acids in VHH confers greater solubility to these antibodies.

[0019] Nanobodies are the smallest known antigen-binding fragments (2.5 nm in diameter and 4 nm in length) generated using recombinant DNA technology. Their isolation paved the way for the production of fully active, stable, soluble, specific, high-affinity, non-immunogenic, and humanizable single-stranded antibodies.

[0020] Nanobodies have unique properties such as the ability to recognize epitopes not recognized by other antibodies and their enhanced stability. Furthermore, they have been successfully used in therapeutic approaches as receptor blockers associated with various diseases or pathogenic viruses. For administration to humans, these nanobodies must be humanized, as was done in the case of caplacizumab, the first approved drug developed with a nanobody [3]. The blood-brain barrier (BBB) ​​is a highly selective filter that controls and restricts the passage of molecules between the bloodstream and the brain parenchyma. Among the different cell types that compose it, the microvascular endothelial cells of the brain form tight and adherent junctions that force transcytosis as the only mechanism for the transport of molecules from the bloodstream across the capillary wall into the CNS or vice versa.It is estimated that the BBB blocks the transport of approximately 98% of molecules, which represents a major challenge for the treatment of CNS diseases.

[0021] DESCRIPTION OF THE INVENTION

[0022] This document describes a novel nanobody capable of specifically binding to HSV-1, HSV-2, and VZV and crossing the blood-brain barrier (BBB). This nanobody is obtained by modifying the nucleotide sequence, and consequently the amino acid sequence, of a specific HSV-1 neutralizing nanobody, NbHSV69B, previously developed by this research team and described in Spanish patent application P202330955. In this invention, the nanobody is modified by adding the transferrin receptor ligand (TfRL) sequence to increase its permeability across the BBB, thus enabling its use in the diagnosis and treatment of infection caused by the human alpha-herpesviruses HSV-1, HSV-2, and VZV, both locally and in the central nervous system (CNS), thanks to its ability to cross the BBB.The transferrin receptor (TfR) is a receptor specific to the BBB that is highly expressed in the cells that make up the barrier.

[0023] The nanoantibody of the present invention, also called NbHSV69B-TfRL, is obtained by adding the TfRL sequence to the NbHSV69B nanoantibody as shown in Figure 1.

[0024] Patent application P202330955 described how the starting nanobody against HSV-1, NbHSV69B, binds to the HSV-1 gB glycoprotein, promoting its neutralization (Figure 4). This HSV-1 neutralization capacity is maintained in the NbHSV69B-TfRL nanobody because the epitope recognition sequence of NbHSV69B has not been modified (Figure 11). Given the high percentage of identity of the amino acid sequences of the gB glycoprotein of HSV-1 and HSV-2 viruses (88%) (Figure 2), the neutralization of HSV-2 through the recognition of HSV-2-infected cells (Figure 6) is also achieved via the same epitope in the gB glycoprotein previously identified for HSV-1.

[0025] In vitro tests with VZV prove that the NbHSV69B-TfRL nanoantibody also allows specific recognition of VZV-infected cells (Figure 7) even though, in this case, the percentage of identity with the amino acid sequence of the HSV-1 virus gB glycoprotein is lower, at (49%) (Figure 3).

[0026] Thus, it is confirmed that NbHSV69B-TfRL recognizes the same epitope in all three cases, that is, in Herpes Simplex 1 and 2 and in VZV.

[0027] Binding to the same epitope confers upon the NbHSV69B-TfRL nanobody a broad spectrum of ability to detect and neutralize human alpha-herpesviruses, affecting HSV-1, HSV-2, and VZV. It is worth recalling that gB plays a crucial role in the virus's infection machinery, as previously mentioned, since viral infection is closely linked to the presence of this protein. The binding between the nanobody of the invention and gB affects the insertion of hydrophobic fusion loops in the cell membrane, limiting the infectivity of the human alpha-herpesviruses HSV-1, HSV-2, and VZV.

[0028] Therefore, the mechanism of action on which the inhibition of infection by these viruses is based is common among them and differs entirely from the target on which the drugs currently available on the market for the treatment of Herpes virus infections act, such as those mentioned previously: ACV, famciclovir and valaciclovir.

[0029] The examples in this report demonstrate that the nanoantibody NbHSV69B-TfRL has in vitro antiviral activity against HSV-2, neutralizing the infection of Vero cell cultures at significantly lower concentrations than ACV (Figure 5), the reference compound used as a control, exhibiting different mechanisms of action as already noted.

[0030] The addition of the transferrin receptor ligand (TfRL) does not negatively affect the binding capacity of the NbHSV69B-TfRL nanobody to the epitope on the gB glycoprotein of human alpha-herpesviruses and, therefore, its ability to neutralize these viruses. Evidence of this is that, when comparing the capacity of the starting nanobody (NbHSV69B) to neutralize HSV-1 (Figure 4) with that of the nanobody of the invention (NbHSV69B-TfRL) to neutralize HSV-2 (Figure 5), this capacity is not only maintained in the modified NbHSV69B-TfRL nanobody, but is actually increased.

[0031] The nanobody is also shown to be selective for the human alpha-herpesviruses HSV-1, HSV-2, and VZV. This is confirmed in immunofluorescence assays, where it is observed that this nanobody marks the proteins expressed on the surface of Vero or MRC-5 cells when infected by HSV-2 or VZV, respectively (Figures 6 and 7), while uninfected cells do not fluoresce, demonstrating its specificity.

[0032] For its part, patent application P202330955 already reported the specificity of the starting nanobody, NbHSV69B, in selectively marking proteins expressed on the surface of Vero cells when infected by HSV-1 (Figure 8). This specificity against HSV-1 is maintained for the NbHSV69B-TfRL nanobody since the epitope recognition sequence of NbHSV69B has not been modified (Figure 11).

[0033] Therefore, the nanoantibody of the invention, NbHSV69B-TfRL, can be used for the diagnosis of infections by the human alpha-herpesviruses HSV-1, HSV-2 and VZV.

[0034] This use for the diagnosis of infections by the human Alpha-herpesviruses HSV-1, HSV-2 and VZV can be extended even to the level of the CNS due to their ability to cross the BBB.

[0035] This latter fact is demonstrated in an assay performed with an in vitro BBB cell model, where it can be observed how the nanoantibody of the invention is able to cross the BBB practically twice as far (Figure 9) as the HSV-1 neutralizing nanoantibody without TfRL. (NbHSV69B).

[0036] This report also describes the procedure for obtaining the NbHSV69B-TfRL nanoantibody.

[0037] The NbHSV69B-TfRL nanobody or “nanobody of the invention” in the context of the present invention, is defined as the protein with the amino acid sequence SEQ. ID. No.: 2, where SEQ. ID. No.: 2:

[0038] The nanoantibody NbHSV69B-TfRL is also defined by the nucleic acid molecule that constitutes the protein coding sequence collected in SEQ. ID. No.: 2, and which would comprise various variants from:

[0039] a) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ. ID. No.: 2,

[0040] b) nucleic acid molecules whose complementary strand is hybrid with the polynucleotide sequence of a),

[0041] c) nucleic acid molecules whose sequence differs from a) and / or ob) due to the degeneracy of the genetic code,

[0042] d) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence having an identity of at least 90%, 95%, 98% or 99% with SEQ. ID No.: 2, and wherein the polypeptide encoded by said nucleic acids possesses the activity and structural characteristics of the NbHSV69B-TfRL nanoantibody.

[0043] Among these nucleic acid molecules is the one collected in the sequence named here as SEQ. ID No.: 1:

[0044] ATGGCCACCCATCGTCCGCCGATGTGGAGCCCGGTTTGGCCTGGTGGCATGGCCC AGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGA GACTCTCCTGTGCAGCCTCTATAGACAACTTCAGAGGGTATTCGGTGGGCTGGTTC CGCCAGGCTCCAGGGAAGGAACGTGAGTGGGTGTCAGGTATTGAGCTGGTTATG AATGGCCAGTTTACGCCGACTCCGTGAAGGGCCGATTCACCCTCCCGAGACAA CGTCAAGAACGTGGTGTACCTACAAATGAACAGCCCTGAAACCTGAGGACACGGCC ATCTATTACTGTGCGGCCGGCATAACATACGGCGCGTATAATTATTGGGGCCAGGG GACCCAGGTCACCGTCTCCTCAGCGGCCGCATACCCGTACGGTTCCGGACTAC GGTTCCCACCACCATCACCATCACTGT

[0045] The terms “polynucleotide” and “nucleic acid” are used here interchangeably, referring to polymeric forms of nucleotides of any length, both hbonucleotides (RNA) and deoxyribonucleotides (DNA).

[0046] The terms “amino acid sequence”, “peptide”, “oligopeptide”, “polypeptide” and “protein” are used here interchangeably, and refer to a polymeric form of amino acids of any length, which may be coding or non-coding, chemically or biochemically modified.

[0047] Therefore, a first aspect of the invention relates to the isolated NbHSV69B-TfRL nanoantibody of amino acid sequence SEQ. ID. No.: 2, or isolated protein with an identity of at least:

[0048] a) 90% with the SEQ. ID. No.: 2,

[0049] b) 95% with the SEQ. ID. No.: 2,

[0050] c) 99% with the SEQ. ID. No.: 2,

[0051] and that possesses the activity and structural characteristics of the NbHSV69B-TfRL nanobody or nanobody of the invention.

[0052] A second aspect of the invention relates to the isolated nucleic acid of amino acid sequence SEQ. ID. No.: 1 that encodes the nanoantibody NbHSV69B-TfRL.

[0053] A third aspect of the invention relates to a vector comprising the isolated nucleic acid of amino acid sequence SEQ. ID. No.: 1 encoding the nanoantibody NbHSV69B-TfRL.

[0054] A fourth aspect of the invention relates to a host cell comprising the nucleic acid of amino acid sequence SEQ. ID. No.: 1 or the vector comprising it.

[0055] A fifth aspect of the invention relates to a composition comprising the nanoantibody of the invention, the nucleic acid of amino acid sequence SEQ. ID. No.: 1, the vector comprising said nucleic acid, or the aforementioned host cell, hereinafter referred to as the “composition of the invention.” Preferably, the composition of the invention is a pharmaceutical composition. More preferably, it further comprises a pharmaceutically acceptable vehicle and / or pharmaceutically acceptable excipients. In a preferred embodiment of the composition of the invention, it further comprises another active ingredient.

[0056] A sixth aspect of the invention relates to the nanoantibody of the invention, the nucleic acid of amino acid sequence SEQ. ID. No.: 1, the vector comprising said nucleic acid, the aforementioned host cell, or the composition of the invention in any of its embodiments for use in the preparation of a medicament for the treatment of infection caused by a virus of the Orthoherpesviridae family, preferably one that produces disease in humans. More preferably, the virus of the Orthoherpesviridae family is selected from the list consisting of HSV-1, HSV-2, VZV, Epstein-Barr virus, cytomegalovirus (CMV), roseola infantum virus or HSV-6, HSV-7, and Kaposi's sarcoma virus or HSV-8.

[0057] More preferably, the invention relates to the nanoantibody of the invention, the nucleic acid of amino acid sequence SEQ. ID. No.: 1, the vector comprising said nucleic acid, the aforementioned host cell, or the composition of the invention in any embodiment thereof for use in the preparation of a medicament for the treatment of infection caused by a human alpha-herpesvirus, which is selected from the list consisting of: HSV-1, HSV-2 ZM.

[0058] Preferably, the infection caused by the virus affects the central nervous system. In an even more preferred embodiment, the infection caused by the virus affects the central nervous system, causing herpes encephalitis. Herpes encephalitis is a serious infection of the central nervous system that causes a type of encephalitis associated with the herpes simplex virus (HSV). Most cases of herpes encephalitis are caused by HSV-1, and only 10% of cases are due to HSV-2. Other herpesviruses, such as VZV, can cause similar symptoms and may lead to serious complications, such as encephalitis and meningitis, with a mortality rate of up to 15%, pneumonia, and, most commonly, postherpetic neuralgia, a prolonged nerve pain.

[0059] A seventh aspect of the invention relates to the nanoantibody of the invention for use in a diagnostic method for infection caused by a virus of the Orthoherpesviridae family, preferably a human alpha-herpesvirus, which is preferably selected from the list consisting of HSV-1, HSV-2 and VZV.

[0060] An eighth aspect of the invention relates to the method for diagnosing infection caused by a virus of the Orthoherpesviridae family, preferably by a human alpha-herpesvirus, more preferably by HSV-1, HSV-2 and / or VZV, which is carried out on a previously isolated tissue sample that has lesions compatible with infection caused by these viruses and which comprises:

[0061] a) infecting a cell culture with said isolated sample, preferably Vero cells for Herpes Simplex viruses type 1 and 2, and MRC-5 cells for Herpes Zoster virus, b) incubating the infected cell culture, preferably Vero or MRC-5 cells, together with the nanoantibody of the invention,

[0062] c) carry out a test that allows the detection of the nanoantibody of the invention bound to the cells of the cell culture, preferably by immunofluorescence.

[0063] Preferably, the immunofluorescence test is performed as described below. The presence of fluorescence in the culture is indicative of Alpha-herpesvirus infection, regardless of the fluorescence level.

[0064] A ninth aspect of the invention relates to a diagnostic kit comprising nanoantibody of the invention and means for detecting the specific binding of the nanoantibody to the human alpha-herpesviruses HSV-1, HSV-2 and / or VZV.

[0065] A tenth aspect of the invention relates to the in vitro use of the diagnostic kit according to the preceding claim to carry out the diagnostic method of the invention.

[0066] Another aspect of the invention relates to the nanoantibody of the invention, the nucleic acid of amino acid sequence SEQ. ID. No.: 1, the vector comprising said nucleic acid, the host cell referred to above, or the composition of the invention in any of its embodiments for use in the treatment of a patient having an infection identified by the in vitro diagnostic method of the invention or with the diagnostic kit of the invention.

[0067] A final aspect of the invention describes the procedure for modifying the NbHSV69B nanobody to obtain the nanobody of the invention, comprising:

[0068] a. amplify by PCR the neutralizing nanoantibody NbHSV69B cloned into a phagemid vector to add the transferrin receptor ligand (TfRL) sequence to the amino terminus,

[0069] b. clone and amplify in Escherichia coli the amplified nanoantibody bound in a phagemid vector.

[0070] Throughout the description and claims, the word "comprises" and its variations are not intended to exclude other technical features, additives, components, or steps. For those skilled in the art, other objects, advantages, and features of the invention will become apparent partly from the description and partly from the practice of the invention. The following examples and drawings are provided for illustrative purposes and are not intended to limit the scope of the present invention.

[0071] BRIEF DESCRIPTION OF THE FIGURES

[0072] Figure 1: Representation of the process of adding the TfRL DNA sequence and two hinge glycines to the HSV-1 neutralizing nanoantibody NbHSV69B by PCR.NbHSV69B C-ter is the part of the primer DNA sequence corresponding to the C-terminal end of the nanobody cloned into the pMES4 vector; NbHSV69B N-ter is the part of the primer DNA sequence corresponding to the N-terminal end of the nanobody cloned into pMES4; Stop-BstEII_R is the part of the primer DNA sequence at the C-terminal end to add the stop codon and the restriction enzyme BstEII; Pstl_F-TfRL-Gly is the part of the primer DNA sequence at the N-terminal end to add the restriction enzyme Pstl, the transferrin receptor ligand (TfRL), and two glycines that act as hinges to the nanobody; NbHSV69B -pMES4 is the DNA sequence of the nanobody cloned into pMES4 (the detail of each strand of the dsDNA is shown in the enlarged figure after enzymatic digestion). Image created with BioRender.

[0073] Figure 2: Percentage of identity between the amino acid sequences of the gB glycoprotein of HSV-1 and HSV-2 viruses after performing an NCBI BLAST®: 88%. Analysis performed with the Vector NTI Advance tool.

[0074] Figure 3: Percentage of identity between the amino acid sequences of the gB glycoprotein of HSV-1 and VZV after performing an NCBI BLAST®: 49%. Analysis performed with the Vector NTI Advance tool.

[0075] Figure 4: HSV-1 100TCID50 neutralization assays in Vero cells. Percentage of cell viability in the different assays performed, with varying concentrations of the NbHSV69B nanoantibody and ACV, used as a positive control. The line labeled 50 indicates 50% cell viability in the uninfected and untreated control cells, as well as the minimum neutralizing concentration of ACV or the NbHSV69B nanoantibody using HSV-1 100TCID50. Mean values ​​with their standard deviation.

[0076] Figure 5: HSV-2 100TCID50 neutralization assays in Vero cells. Percentage of cell viability in the different assays performed, with varying concentrations of the invention's nanoantibody NbHSV69B-TfRL and ACV, used as a positive control. The line labeled 50 indicates 50% cell viability in the control of uninfected and untreated cells, as well as the minimum neutralizing concentration of ACV or the invention's nanoantibody using HSV-2 100TCID50. Mean values ​​with their standard deviation and statistical analysis with p-values ​​obtained using a parametric t-test performed in GraphPad Prism version 9. Significant differences p < 0.0001 (****).

[0077] Figure 6: Immunofluorescence (IF) assay of the nanoantibody of the invention NbHSV69B-TfRL against HSV-2 virus. Images obtained by confocal microscopy. The fluorophore used in each case is indicated at the top and in columns: DAPI, which stains nuclear DNA, and A488 (Alexa 488), which is used for the antibody binding signal. o Anti-mouse. The "Merge" refers to the two superimposed images on the left, showing DAPI and A488 together. The different conditions used in the IF are indicated in rows on the left. Vero / NbHSV69B-TfRL+2Abs: Vero cells uninfected with the nanobody of the invention and the two secondary antibodies (Anti-HA and anti-mouse A488); Vero / HSV-2 / 2Abs: Vero cells infected with the HSV-2 virus and incubated with the two secondary antibodies; Vero / HSV-2 / NbHSV69B-TfRL+2Abs: Vero cells infected with the HSV-2 virus and incubated with NbHSV69B-TfRL at 20 ng / pl plus the two secondary antibodies.

[0078] Figure 7: Immunofluorescence (IF) assay of the nanoantibody of the invention NbHSV69B-TfRL against VZV virus. Images obtained by confocal microscopy. The fluorophore used in each case is indicated in the top and in columns: DAPI, which stains nuclear DNA, and A488 (Alexa 488), which is used for the antibody binding signal. o Anti-mouse. The "Merge" refers to the two superimposed images on the left, showing DAPI and A488 together. The different conditions used in the IF are indicated in rows on the left. MRC-5 / NbHSV69B-TfRL+2Abs: MRC-5 cells uninfected with the nanoantibody of the invention and the two secondary antibodies (Anti-HA and anti-mouse A488); MRC-5A / ZV / 2Abs: MRC-5 cells infected with VZV virus and incubated with the two secondary antibodies; MRC-5A / ZV / NbHSV69BTfRL+2Abs: MRC-5 cells infected with VZV virus and incubated with NbHSV69B-TfRL at 20 ng / pl plus the two secondary antibodies.

[0079] Figure 8: Immunofluorescence assay. Images obtained by fluorescence microscopy. (A) HSV-1 infected Vero cell in the presence of the NbHSV69B nanobody plus primary anti-hemagglutinin (HA) antibodies (Biolegend, purified antiHA.11 Epitope Tag Antibody) and secondary anti-mouse antibodies conjugated with Alexa 488 (A11001, Life Technologies), detecting viral surface proteins on the cell membrane. Cell nuclei stained with 4',6-diamidino-2-phenylindole (DAPI) are shown in color. (B) HSV-1 infected Vero cells without NbHSV69B with primary and secondary antibodies. (C) HSV-1 uninfected Vero cell in the presence of the NbHSV69B nanobody plus primary and secondary antibodies. (D) Vero cells not infected by HSV-1 without NbHSV69B with primary and secondary antibodies.

[0080] Figure 9: Time-dependent translocation of peptides and the nanobody of the invention across an in vitro model of the blood-brain barrier (BBB). The peptides used for this assay, as shown in the legend in descending order, were Angiopep-2-Cy5.5 as a positive translocation control, the nanobody of the invention NbHSV69B-TfRL-Cy5.5, and the HSV-1 neutralizing nanobody NbHSV69B-Cy5.5. All were labeled with the fluorophore Cy5.5. Proper barrier function was validated using the CF 770 dextran diffusion assay at less than 6%.

[0081] Figure 10: Map of the pMES4 phagemid and sequence landmarks (GenBank: GQ907248.1). Lac UV5 promoter: bases 143-198; RBS (ribosome binding site): bases 211-215; pelB (signal peptide): bases 225-290; Multiple cloning site (Pst I, Xba I, Bst Eli): bases 305-325; His-tag (six histidines in tandem): bases 340-357; HA tag (hemagglutinin): bases 361-385; M13 bacteriophage gene III: bases 391-1623; ampicillin resistance: bases 2701-3558.

[0082] Figure 11: Comparison between the amino acid sequences of the nanoantibody of the invention NbHSV69B-TfRL and the starting nanoantibody NbHSV69B.

[0083] Figure 12: Graph of the results of the neutralization assay with NbHSV69B, with and without TfRL, ACV, and NbHSV44 as a negative control at a dose of 100 TCID50 of HSV-1 virus. The Y-axis shows the percentage of cell viability (50% is marked with a dashed line) and the X-axis shows the pM concentration of nanobody or ACV. Each nanobody and ACV are marked with a different bar color as indicated in the figure. Significant differences p <0.01 (**); p <0.001 (***).

[0084] Figure 13: Immunofluorescence (IF) assay of the nanoantibody NbHSV69B-TfRL and NbHSV69B against HSV-1 virus. Images obtained by confocal microscopy. The fluorophore used in each case is indicated in the top and in columns: DAPI, which stains nuclear DNA, and A488 (Alexa 488), which stains the antibody-binding signal. oAnti-mouse. “Merge” refers to the two superimposed images on the left, showing DAPI and A488 together. The different conditions used in the IF are indicated in rows on the left. Vero: Vero cells uninfected with the nanoantibody of the invention and the two secondary antibodies (Anti-HA and anti-mouse A488); Vero / HSV-1 / 2Abs: Vero cells infected with the HSV-1 virus and incubated with the two secondary antibodies; Vero / HSV-1 / NbHSV69B+2Abs: Vero cells infected with the HSV-2 virus and incubated with NbHSV69B at 20 ng / pl plus the two secondary antibodies; Vero / HSV-1 / NbHSV69B-TfRL+2Abs: Vero cells infected with the HSV-2 virus and incubated with NbHSV69B-TfRL at 20 ng / pl plus the 2 secondary antibodies.

[0085] Figure 14: Graph of the results of the neutralization assay with NbHSV69B, with and without TfRL, ACV, and NbHSV44 as a negative control at a dose of 100 TCID50 of the HSV-2 virus. The Y-axis shows the percentage of cell viability (50% is marked with a dotted line) and the X-axis shows the pM concentration of Nb or ACV. Each nanoantibody and ACV are marked with a different bar color indicated in the figure, p <0.01(**); p <0.0001 (****).

[0086] DETAILED DESCRIPTION OF THE INVENTION

[0087] Cell and virus cultures used for the tests.

[0088] Vero cells (African green monkey kidney cells) and MRC-5 cells (human fibroblasts derived from lung tissue) were maintained in DMEN (Dulbecco's Modified Eagle Medium) High Glucose medium (Biowest, L0103), supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (Sigma Aldrich, 10270106), 100U / ml Penicillin, 100ug / ml Streptomycin (Sigma Aldrich, P0781) and 1% L-Glutamine (Sigma Aldrich, G8540) in a humidified environment at 37°C and 5% CO2.

[0089] The HSV-2 virus was provided by Dr. Sara Luisa Sanbonmatsu Gámez from the Clinical Management Unit of Microbiology at the Virgen de las Nieves University Hospital in Granada and was propagated following her recommendations in VERO cells with a biosafety level 2. The live VZV virus with reference VR-1367™ was acquired from ATCC, Rockville, MD, USA, and was propagated following their recommendations in MRC-5 cells with a biosafety level 2.

[0090] HSV-1 neutralizing nanoantibody

[0091] The process for obtaining the starting nanobody (NbHSV69B) for the preparation of the nanobody of the present invention (NbHSV69B-TfRL) is described in patent application P202330955 of this same research group. Briefly, to generate a nanobody library [5, 6], a camel was immunized with inactivated HSV-1 virus for six weeks, administering weekly doses and collecting serum samples before and after the process to evaluate the immune response using an ELISA assay. After confirming effective immunization, peripheral blood mononuclear cells (PBMCs) were isolated for the construction of a nanobody library. From the mRNA extracted from the PBMCs, reverse transcription to cDNA was performed, and specific VHH sequences were amplified by PCR. These sequences were cloned into a phagemid vector and transformed into E cells.coli, and infected with a helper phage to generate a library of nanoantibodies in phage particles.

[0092] Subsequently, selection rounds (biopanning) were performed on HSV-1 coated plates to enrich phage particles with specific affinity for the antigen. After two independent biopanning runs of three rounds each, 285 candidates were selected. These were evaluated by ELISA to determine their specificity, discarding those with low affinity and ultimately yielding 272 positive clones. These nanobodies were sequenced using the Sanger method, and the resulting sequences were grouped into eight distinct clusters based on their similarity. One representative from each cluster was selected and classified as VH or VHH according to structural criteria defined by the IMGT database.

[0093] The eight representative nanobodies were expressed in the E. coli WK6 strain and purified by rapid protein liquid chromatography (FPLC) [7]. The concentration of the purified proteins was determined using the Bradford method, thus completing the process of generating and characterizing specific nanobodies against HSV-1.

[0094] Only one of these nanobodies had the neutralizing capacity of 100TCID50 of the HSV-1 virus on Vero cells in an in vitro assay. This nanobody was named NbHSV69B and is defined as the protein with the amino acid sequence SEQ. ID. No.: 3:

[0095] MAQVQLQESGGGSVQAGGSLRLSCAASIDNFRGYSVGWFRQAPGKEREWVSGIEAG YEWPVYADSVKGRFTLSRDNVKNWYLQMNSLKPEDTAIYYCAAGITYGAYNYWGQG TQVTVSSAAAYPYDVPDYGSH HHHHH .

[0096] The NbHSV69B nanoantibody is encoded by the SEQ sequence nucleic acid. ID. No.: 4:ATGGCCCAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGG TCTCTGAGACTTCCTGTGCAGCCTCTATAGACAACTTCAGAGGGTATTCGGTGGG CTGGTTCCGCCAGGCTCCAGGGAAGGAACGTGAGTGAGTGGGTGTCAGGGGGCTTATT GGTTATGAATGGCCAGTTTACGCCGACTCCGTGAAGGGCCGATTCACCCTCTCCC GAGACAACGTCAAGAACGTGGTGTACCTACAAATGAACAGCCCTGAAACCTGAGGAC ACGGCCATCTATTACTGTGCGGCCGGCATAACATACGGCGTATATTGGGG CCAGGGGACCCAGGTCACCGTCTCCTCAGCGGCCGCATACCCGTACGACGTTCCG GACTACGGTTCCCACCACCATCACCACACAC

[0097] In a viral neutralization assay performed with NbHSV69B on Vero cells with a VSH-1 virus TCID50 titer of 4.22x10 5The concentration of cells per ml calculated using the Spearman-Karber method, and defining as neutralizing those wells in which there was a viability equal to or greater than 50% of the mean of the control cells, showed a capacity to neutralize HSV-1 cell infection similar to that of acyclovir. These results are reproduced in Figure 4.

[0098] It was also found that the NbHSV69B nanobody labeled proteins expressed on the surface of Vero cells when infected by HSV-1, while uninfected cells did not fluoresce, demonstrating its specificity. These results are shown in Figure 8.

[0099] The methodology by which these tests were carried out with the NbHSV69B nanobody is the same as that described in more detail below for the nanobody of the invention: NbHSV69B-TfRL.

[0100] Modification of the HSV-1 neutralizing nanoantibody with the addition of TfRL to cross the BBB

[0101] The coding sequence of the transferrin receptor ligand (TfRL) was added to the coding sequence of the NbHSV69B nanobody in order to be able to cross the BHE and thus be able to treat diseases caused by Alpha-herpesviruses at the level of the CNS.

[0102] The NbHSV69B nanobody was linked to the TfRL sequence with a two-glycine hinge at the 5' end (Figure 1).

[0103] The coding sequence for TfRL used was SEQ. ID. No.:5:

[0104] The following oligonucleotides were designed to amplify by PCR the DNA fragment of the HSV-1 neutralizing nanoantibody cloned into the pMES4 vector.

[0105] Pstl_F-TfRL-Gly-NbHSV69B_N-ter: SEQ. ID. No.: 6:

[0106] 5'- CTTGGCTCTTCTGTGACCCATCGTCCGCCGATGTGGAGCCCGGTTTGGCCTGGTG GCATGGCCCAGGTGCAGCTG- 3'

[0107] BstEII_R-Stop-NbHSV69B_C-ter: SEQ. ID. No.: 7:

[0108] 5'-TGATGCTCTTCCGCTCTAACAGTGATGGTGATGGTGGTG-3'

[0109] The reaction was carried out using 0.5 pl of Phusion High-Fidelity DNA polymerase 2 ll / pl (F530, Thermo Fisher) and 7.5 ng of DNA (pMES4 nanoantibody). The PCR cycles were 98 °C, 30 seconds and 35 cycles of (98 °C, 10 seconds; 56 °C, 30 seconds; 72 °C, 15 seconds) with a final cycle of 72 °C, 10 minutes. The resulting fragment was cleaned with the “Gen Elute PCR clean-up” kit and digested with the restriction enzymes Pstl-HF and BstEII-HF (Figure 1).

[0110] Ligation with the phagemid vector pMES4 (GenBank: GQ907248.1) (Figure 10) was performed with DNA ligase T4 and the product was transformed into E. coli WK6 to perform the expression and purification process of NbHSV69B-TfRL.

[0111] Homology study between the gB glycoproteins of Alpha-herpesviruses HSV-1 and HSV-2.

[0112] To analyze the homology between HSV-1 and HSV-2 viruses, an alignment was performed using the gB glycoproteins of HSV-1 and HSV-2. The following GenBank sequences were used: AAA45778.1 for the gB glycoprotein of HSV-1 and AIL27715.1 for the gB glycoprotein of HSV-2. The results of this study are shown in Figure 2, where the degree of identity between the two proteins, analyzed using the Vector NTI Advance and NCBI BLAST® tools, is 88%.

[0113] Determination of the TCID50 of the HSV-2 virus.

[0114] An assay was performed to determine the number of infectious particles of HSV-2 needed to achieve a 50% infection of the culture (TCID50) following the Spearman-Karber method as previously described by [8, 9]. Briefly, 10 4Vero cells / well in 96-well plates, minus column 12, were incubated for 24 hours. Seated dilutions were performed (10' 1 — 10' 7 ) from the virus stock in Minimum Essential Medium (MEM) (Biowest, L0430), with 2% inactivated Fetal Bovine Serum (Sigma Aldrich, 10270106) and 50U of Penicillin, 50 pg of Streptomycin (Sigma Aldrich, P0781), and 100 pl of each dilution were added to each well of the 96-well plate. In addition, wells with uninfected cells were placed as a cell control (CC) in column 11 and column 12 as a developer control. The plates were incubated at 37°C and 5% CO2 for 2 days for HSV-1 and 3 days for HSV-2.

[0115] Cell viability was determined by staining with Neutral Red developer (Sigma Aldrich, N4638) following protocol [9] using 80% acetone (Scharlau, AC03141000) in DPBS (Sigma Aldrich, D8537) as a fixative.

[0116] The TCID50 titer of the HSV-2 virus was 1.78x10 6 / ml, calculated according to the Spearman-Karber method [8],

[0117] HSV-2 viral neutralization assay.

[0118] Vero cells were seeded in 96-well plates at 10 4cells / well, leaving column 12 empty, and were incubated overnight at 37°C and 5% CO2. The nanoantibody of the invention NbHSV69B-TfRL and ACV (Sigma Aldrich, PHR1254), as a positive neutralization control, were diluted in Minimum Essential Medium (MEM) (Biowest, L0430), 2% Heat-Inactivated Fetal Bovine Serum (Sigma Aldrich, 10270106), and 100 U / ml Penicillin, 100 pg / ml Streptomycin (Sigma Aldrich, P0781) to an initial concentration of 20 pM, making seated dilutions 1 in a final volume of 50 pl. In column 9, eight wells were used as a virus infection control (100TCID50 / well) in 100 pl. In column 10, a virus titration control was performed by making 1 / 10 seeded dilutions of the previously titrated viruses in 100 pl. In column 11, eight wells were used for CC in 100 pl.Dilutions of the nanobody and ACV were mixed with an equal volume of HSV-2 virus (50 pl) diluted to produce 100 TCID50 / well and incubated for 1 hour in a humidified environment at 37°C and 5% CO2. After incubation, the virus-nanobody or virus-ACV mixtures were transferred to pre-seeded cells washed with DPBS (Sigma Aldrich, D8537). These were incubated for 72 hours at 37°C and 5% CO2. Cell viability was determined by staining with Neutral Red (Sigma Aldrich, N4638) following the same protocol described for TCID50 determination. Wells with viability equal to or greater than 50% of the mean cell control were defined as neutralizing.

[0119] Figure 5 shows the results of the neutralization assay against HSV-2. The 50 line marks 50% of the cell viability calculated with the CC. Above this line, cell viability is high, and therefore the infection of cells by the virus is small.

[0120] In this assay, it was determined that the nanoantibody of the invention (NbHSV69B-TfRL) is capable of neutralizing HSV-2 infection of Vero cells at a minimum dose of 1.25 pM. Furthermore, a statistical analysis was performed using a parametric t-test in GraphPad Prism version 9, where p-values ​​<0.01 were considered statistically significant. The results indicated a statistically significant difference in antiviral activity between NbHSV69B-TfRL and ACV (the selection treatment) at the minimum neutralizing concentrations of 2.5 and 1.25 pM, with a p-value <0.0001 (****).

[0121] HSV-2 immunofluorescence.

[0122] Vero cells were seeded onto 13 mm circular coverslips placed in 24-well plates and incubated overnight to allow adhesion. The cells were infected with 0.5 ml of the HSV-2 virus dilution that had previously generated 50% cell viability, a finding confirmed by microscopic observation of the cultures. This dilution corresponded to the 10⁻⁵ dilutions. 3From the same batch of amplified and titrated viruses for the neutralization assays. To the control of uninfected cells, 0.5 ml of virus-free medium was added. They were incubated for 48 hours in a humidified environment at 37°C and 5% CO2. After 48 hours post-infection, the medium was removed and the cells were washed three times with DPBS and then fixed with 4% (v / v) PFA for 10 minutes at room temperature. The fixative was removed, the cells were washed three times with DPBS, and blocked with 10% bovine serum albumin (BSA) (A7906, Sigma Aldrich) for 60 minutes at room temperature.

[0123] After incubation, infected and uninfected cells were washed with DPBS and both were incubated with the nanoantibody of the invention, NbHSV69B-TfRL. 200 µl of the Nb was added to each well to a final concentration of 20 ng / µl. The cells were incubated overnight at 4°C (ON). Wells without added nanoantibody were incubated with 200 µl of dilution buffer. Three washes were performed after incubation.

[0124] The primary antibody used was the mouse anti-hemagglutinin (HA) monoclonal antibody (Biolegend, purified anti-HA.11 Epitope Tag Antibody) at a 1 / 500 dilution in dilution buffer. The samples were incubated for 1 hour at room temperature and, after washing, were incubated with the secondary antibody (Alexa 488 conjugated anti-mouse) (A11001, Life Technologies) at a 1 / 500 dilution in dilution buffer for 30 minutes at 4°C in the dark.

[0125] The test conditions were as follows: infected Vero cells (HSV-2) plus NbHSV69B-TfRL plus primary and secondary antibodies (2Abs), infected Vero cells (HSV-2) without NbHSV69B-TfRL with primary and secondary antibodies (2Abs), and uninfected cells with NbHSV69B-TfRL plus primary and secondary antibodies (2Abs).

[0126] Finally, all coverslips were mounted on slides (J2800AMNZ, Thermo Fisher Scientific) with Vectashield (H-1200, Vector), including DAPI for nuclear counterstaining.

[0127] The images were taken using an LSH710 confocal microscope (Zeiss) with a 63x oil immersion objective and analyzed with the ZEN blue (Zeiss) and Imaged software programs. The images (Figure 6) were captured from randomly selected fields of view.

[0128] It is observed that the nanoantibody NbHSV69B-TfRL marks the proteins expressed on the surface of Vero cells when infected by HSV-2 viruses, while uninfected cells do not show fluorescence (A488), which demonstrates its specificity.

[0129] Homology study between the gB glycoproteins of the Alpha-herpesviruses HSV-1 and VZV.

[0130] To analyze the homology between HSV and VZV viruses, an alignment was performed using the gB glycoproteins of HSV-1 and VZV. The following GenBank sequences were used: AAA45778.1 for the gB glycoprotein of HSV-1 and AEW88584.1 for the gB glycoprotein of VZV. The results of this study are shown in Figure 3, where the degree of identity between the two proteins, analyzed using the Vector NTI Advance and NCBI BLAST® tools, is 49%.

[0131] VZV immunofluorescence.

[0132] For this assay, Alpha-herpesvirus / Z / (VR-1367, ATCC) and the MRC-5 cell line (VTMR, Vircell Microbiologists), used for virus isolation, were employed. The immunofluorescence technique was similar to that used with HSV-1 and HSV-2 viruses, adjusting the incubation times for viruses that do not produce ECP but do form syncytia in in vitro culture.

[0133] 6x10 were sown 4 MRC-5 cells / well with 13 mm circular coverslips in 24 well plates, in DMEM (Dulbecco's Modified Eagle Medium) High Glucose (L0103, Biowest) medium, supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (10270106, Sigma Aldrich), 100 U / ml Penicillin, 100 ug / ml Streptomycin (P0781, Sigma Aldrich) (P / E) and 1% L-Glutamine (L-GI) (Sigma Aldrich, G8540) and incubated in a humidified environment for 48 hours at 37 °C and 5% CO2.

[0134] After washing with PBS, the cells were infected with 100 pl per well of stock virus with a titer of 9.2 x 10 3 TCID50 (manufacturer's titer on MRC-5 cells). To the uninfected cell control, 200 ml of virus-free medium was added. The plate was centrifuged for 45 minutes at 800 x g and incubated for 1 hour at 37°C and 5% CO2. Subsequently, medium was added to a volume of 2 ml and the plate was incubated again for 48 hours in a humidified environment at 37°C and 5% CO2. After 48 hours post-infection, the same procedure used for HSV-2 was followed.

[0135] The images were taken using an LSH710 confocal microscope (Zeiss) with a 63x oil immersion objective and analyzed with the ZEN blue (Zeiss) and Imaged software programs. The images (Figure 7) were captured from randomly selected fields of view.

[0136] The results show that the nanoantibody of the invention gave a fluorescence signal in MRC-5 cells infected with the VZV virus, while the negative controls (MRC-5 cells not infected with secondary and tertiary antibodies, and infected without nanoantibody plus the secondary and tertiary antibodies) did not emit any signal.

[0137] This indicated that NbHSV69B-TfRL is also specific in its binding against VZV. In vitro model of BBB entry analysis.

[0138] The objective of this trial was to analyze the ability of NbHSV69B-TfRL to cross the BBB using an in vitro cell model, in which the BMECs cell line (brain microvascular endothelial cells) was used.

[0139] BMEC cells (D3 line) were cultured at 37 °C, 5% CO2 and 95% humidity in T-75 flasks coated with collagen I, using a complete endothelial medium with supplemented vapors (hydrocortisone, bFGF, ascorbic acid, antibiotics, HEPES, L-glutamine and fetal bovine serum).

[0140] To establish a blood-brain barrier (BBB) ​​model, BMECs were seeded onto Transwell cell membrane inserts coated with collagen I and incubated until a monolayer formed. Barrier integrity was assessed by measuring transendothelial electrical resistance (TEER), and was considered acceptable if it reached approximately 100 Ω / cm. 2 Subsequently, the barrier function was validated using the CF 770 dextran diffusion assay, considering a barrier functional if the passage of dextran was less than 6%.

[0141] For this test, the HSV-1 neutralizing nanoantibody NbHSV69B, the nanoantibody of the invention NbHSV69B-TfRL, and angiopep-2, with confirmed barrier-crossing properties, were used, all labeled with the fluorophore Cy5.5.

[0142] As can be seen in the graph of the results obtained from this assay (Figure 9), dextran diffusion below 6% indicated a functional barrier model. Angiopep-2-Cy5.5 crossed the blood-brain barrier (BBB) ​​at a decreasing percentage over time, while the nanobody of the invention crossed the BBB from the first hour measurement, and even at a percentage twice as high as its homolog lacking the transferrin receptor ligand. This demonstrates that the modification of the NbHSV69B nanobody, previously described as neutralizing HSV-1 in its amino acid sequence, had conferred upon it the ability to cross the BBB.

[0143] HSV-1 viral neutralization assay with NbHSV69B vs NbHSV69B-TfRL

[0144] Vero cells were seeded in 96-well plates at 10 4cells / well, leaving column 12 empty and were incubated overnight at 37°C and 5% CO2. The nanoantibody of the invention NbHSV69B-TfRL, NbHSV69B, ACV (Sigma Aldrich, PHR1254) as a positive neutralization control and the nanoantibody NbHSV44 as a negative control were diluted in Minimum Essential Medium (MEM) (Biowest, L0430), 2% Heat-Inactivated Fetal Bovine Serum (Sigma Aldrich, 10270106) and 100 U / ml Penicillin, 100 g / ml Streptomycin (Sigma Aldrich, P0781) to an initial concentration of 20 pM making sequential dilutions 1 in a final volume of 50 pl. In column 9, eight wells were used as a virus infection control (100TCID50 / well) in 100 pl. In column 10, a virus titration control was performed by making serial 1 / 10 dilutions of the previously titrated viruses in 100 pl. In column 11, eight wells were used for CC in 100 pl.Dilutions of the nanobody and ACV were mixed with an equal volume of HSV-1 virus (50 pl) diluted to produce 100 TCID50 / well and incubated for 1 hour in a humidified environment at 37°C and 5% CO2. After incubation, the mixtures of virus and NbHSV69B nanobody, virus and NbHSV69B-TfRL nanobody, virus and NbHSV44, or virus and ACV were transferred to pre-seeded cells washed with DPBS (Sigma Aldrich, D8537). These were incubated for 72 hours at 37°C and 5% CO2.

[0145] Cell viability was determined by staining with Neutral Red (Sigma Aldrich, N4638) following the same protocol described in the determination of TCID50. Wells with a viability equal to or greater than 50% of the mean of the control cells were defined as neutralizing.

[0146] Figure 12 shows the results of the neutralization assay against HSV-1. The 50 line marks 50% of the cell viability calculated with the CC. Above this line, cell viability is high, and therefore the infection of cells by the virus is small.

[0147] The results of this assay show that ACV neutralized up to 5 pM, NbHSV69B up to 2.5 pM, and NbHSV44 as a negative control did not neutralize. It was also observed that the addition of TfRL to NbHSV69B improved its neutralization capacity, lowering the minimum concentration to 1.25 pM, and even achieving 50% cell viability at 0.625 pM in some replicates.

[0148] Statistical comparisons of the concentrations exhibiting cell viability greater than 50% (Figure 12) revealed a statistically significant difference in antiviral activity between NbHSV69B and ACV at 2.5 pM, with a p-value < 0.001 (***). NbHSV69B-TfRL also showed a statistically significant difference in antiviral activity compared to ACV at 2.5 and 1.25 pM, with a p-value < 0.001 (***). Comparing cell viability results between the two NbHSV69B formulations, with and without TfRL, revealed a clear and statistically significant difference in antiviral activity between NbHSV69B-TfRL and NbHSV69B at a concentration of 1.25 pM, with a p-value < 0.01 (**).

[0149] HSV-1 immunofluorescence with NbHSV69B vs NbHSV69B-TfRL

[0150] Vero cells were seeded onto 13 mm circular coverslips placed in 24-well plates and incubated overnight to allow adhesion. The cells were infected with 0.5 ml of the HSV-1 virus dilution that had previously generated 50% cell viability, a finding confirmed by microscopic observation of the cultures. This dilution corresponded to the 10⁻⁵ dilutions. 3From the same batch of amplified and titrated viruses for the neutralization assays. To the control of uninfected cells, 0.5 ml of virus-free medium was added. They were incubated for 48 hours in a humidified environment at 37°C and 5% CO2. After 48 hours post-infection, the medium was removed and the cells were washed three times with DPBS and then fixed with 4% (v / v) PFA for 10 minutes at room temperature. The fixative was removed, the cells were washed three times with DPBS, and blocked with 10% bovine serum albumin (BSA) (A7906, Sigma Aldrich) for 60 minutes at room temperature.

[0151] After incubation, infected and uninfected cells were washed with DPBS and both were incubated with the nanoantibody of the invention, NbHSV69B-TfRL. 200 µl of the Nb was added to each well to a final concentration of 20 ng / µl. The cells were incubated overnight at 4°C (ON). Wells without added nanoantibody were incubated with 200 µl of dilution buffer. Three washes were performed after incubation.

[0152] The primary antibody used was the mouse anti-hemagglutinin (HA) monoclonal antibody (Biolegend, purified anti-HA.11 Epitope Tag Antibody) at a 1 / 500 dilution in dilution buffer. The samples were incubated for 1 hour at room temperature and, after washing, were incubated with the secondary antibody (Alexa 488 conjugated anti-mouse) (A11001, Life Technologies) at a 1 / 500 dilution in dilution buffer for 30 minutes at 4°C in the dark.

[0153] The test conditions were as follows: Vero cells infected (HSV-1) plus NbHSV69B-TfRL plus primary and secondary antibodies (2Abs), Vero cells infected (HSV-1) without NbHSV69B-TfRL with primary and secondary antibodies (2Abs), and cells not infected with NbHSV69B-TfRL plus primary and secondary antibodies (2Abs).

[0154] Finally, all coverslips were mounted on slides (J2800AMNZ, Thermo Fisher Scientific) with Vectashield (H-1200, Vector), including DAPI for nuclear counterstaining.

[0155] Images were taken using an LSH710 confocal microscope (Zeiss) with a 63x oil immersion objective and analyzed with the ZEN blue (Zeiss) and Imaged software programs. The images (Figure 13) were captured from randomly selected fields of view.

[0156] The first two rows of images are negative controls: the first shows uninfected Vero cells, without NbHSV69B and without the secondary and tertiary antibodies to recognize the nanobody, thus ruling out cell autofluorescence; the second shows Vero cells infected only with the secondary and tertiary antibodies. The third row of the figure corresponds to Vero cells infected with NbHSV69B and the secondary and tertiary antibodies. In all rows of images, uniform nuclei stained with DAPI were observed, with fluorescence appearing only in Vero cells infected with NbHSV69B with or without TfRL as the primary antibody. These results demonstrate the ability of NbHSV69B to recognize its epitope on the gB glycoprotein expressed on the membrane of infected cells, since the cells were not permeabilized during the IF technique.

[0157] HSV-2 viral neutralization assay with NbHSV69B vs NbHSV69B-TfRL

[0158] This assay was performed in the same way as the previously described HSV-1 viral neutralization assay with NbHSV69B vs NbHSV69B-TfRL, but using HSV-2 this time.

[0159] The results are shown in Figure 14. ACV neutralized up to 5 pM, although at 2.5 pM it showed cell viability close to 50%. NbHSV69B neutralized up to 2.5 pM, although it also showed cell viability close to 50% at 1.25 pM. And as expected, NbHSV44 did not neutralize. In summary, these results were consistent with those obtained with HSV-1.

[0160] As also shown in Figure 14, the addition of TfRL to NbHSV69B improved its neutralization capacity compared to NbHSV69B alone, lowering the minimum neutralizing concentration to 1.25 pM, as observed in the HSV-1 virus assay. Statistical comparison of concentrations exhibiting cell viability greater than 50% (Figure 14) revealed a statistically significant difference in antiviral activity between NbHSV69B and ACV at a concentration of 2.5 pM, with a p-value < 0.01 (**). NbHSV69B-TfRL also improved the results, as seen with HSV-1, showing statistically significant differences in antiviral activity compared to ACV at 2.5 and 1.25 pM, with a p-value < 0.0001 (****).Comparing the cell viability results between the two nanobodies, with and without TfRL, a clear difference in antiviral activity was observed with statistical significance of NbHSV69B-TfRL over NbHSV69B at concentrations of 2.5 and 1.25 pM with a P value < 0.01 (**).

[0161] References

[0162] 1. Cairns, Tina M., and Sarah A. Connolly. 2021. 'Entry of Alphaherpesviruses'. Current Issues in Molecular Biology 41:63-124. doi: 10.21775 / cimb.041.063.

[0163] 2. Karasneh GA, Shukla D. Herpes simplex virus infects most cell types in vitro: clues to its success. Virol J. 2011 Oct 26;8:481. doi:10.1186 / 1743-422X-8-481. PMID: 22029482; PMCID: PMC3223518.

[0164] 3. Duggan S. Caplacizumab: First Global Approval. Drugs. 2018 Oct; 78(15): 1639- 1642. doi: 10.1007 / S40265-018-0989-0. Erratum in: Drugs. 2018 Dec;78(18):1955. PMID: 30298461; PMCID: PMC6280848.

[0165] 4. Yan J, Li G, Hu Y, Ou W, Wan Y. Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications. J Transí Med. 2014 Dec 10;12:343. doi: 10.1186 / s12967-014-0343-6.

[0166] 5. Romáo, Ema, Vianney Poignavent, Cécile Vincke, Christophe Ritzenthaler, Serge Muyldermans, and Baptiste Monsion. 2018. ‘Construction of High-Quality Camel Immune Antibody Libraries’. Pp. 169-87 in Methods in Molecular Biology. Vol. 1701. Humana Press Inc.

[0167] 6. Vincke, Cécile, Carlos Gutiérrez, Ulrich Wernery, Nick Devoogdt, Gholamreza Hassanzadeh-Ghassabeh, and Serge Muyldermans. 2012. ‘Generation of Single Domain Antibody Fragments Derived from Camelids and Generation of Manifold Constructs’. Methods in Molecular Biology 907:145-76. doi: 10.1007 / 978-1-61779-974-7_8.7. Gotesman M, Wang Y, Madasu SC, Mitchell CA. 2022. ‘Purification of Cytoskeletal Proteins by Fast Protein Liquid Chromatography (FPLC) Using an ÁKTA Start System’. Pp. 237-49 in Cytoskeleton .

[0168] 8. Ramakrishnan, Muthannan Andavar. 2016. ‘Determination of 50% Endpoint Titer Using a Simple Formula’. World Journal of Virology 5(2):85. doi: 10.5501 / wjv.v5.i2.85.

[0169] 9. Repetto, Guillermo, Ana del Peso, and Jorge L. Zurita. 2008. ‘Neutral Red Uptake Assay for the Estimation of Cell Viability / Cytotoxicity’. Nature Protocols 3(7):1125-31. doi: 10.1038 / nprot.2008.75.

Claims

CLAIMS 1. Isolated NBHSV69B-TfRL nanobody of amino acid sequence SEQ. ID. No.: 2, or isolated protein with an identity of at least 95%, or 99% with SEQ. ID. No.: 2 and possessing the activity and structural characteristics of the NBHSV69B-TfRL nanobody.

2. Isolated nucleic acid of sequence SEQ. ID. No.: 1 encoding the nanoantibody NBHSV69B-TfRL according to claim 1.

3. Vector comprising the nucleic acid according to the preceding claim.

4. Host cell comprising the nucleic acid according to claim 2 or the vector according to claim 3.

5. Composition comprising the nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4.

6. The composition according to the preceding claim, characterized in that it is a pharmaceutical composition.

7. The composition according to the preceding claim, further comprising a pharmaceutically acceptable vehicle and / or pharmaceutically acceptable excipients.

8. The composition according to the preceding claim, further comprising another active ingredient.

9. The nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4, or the composition according to any of claims 5 to 8 for use in the treatment of infection caused by Herpes Simplex Virus type 1.

10. The nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4, or the composition according to any of claims 5 to 8 for use in the treatment of infection caused by Herpes Simplex Virus type 2.

11. The nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4, or the composition according to any of claims 5 to 8 for use in the treatment of infection caused by the Varicella Zoster virus.

12. The nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4, or the composition according to any of claims 5 to 8 for use according to any of claims 9 to 11 characterized in that the infection caused by the virus affects the Central Nervous System.

13. The nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4, or the composition according to any of claims 5 to 8 for use in the treatment of herpes encephalitis.

14. The nanoantibody according to claim 1 for use in an in vitro diagnostic method for infection by Herpes Simplex virus type 1, Herpes Simplex virus type 2, or Varicella Zoster virus.

15. An in vitro diagnostic method for infection caused by Herpes Simplex virus type 1, Herpes Simplex virus type 2 and / or Varicella Zoster virus, performed on a previously isolated tissue sample exhibiting lesions compatible with infection caused by Herpes Simplex virus type 1, Herpes Simplex virus type 2 and / or Varicella Zoster virus, comprising: a) infect a cell culture with said isolated sample, b) incubating the infected cell culture together with the nanoantibody according to claim 1, and c) carrying out a test that allows the detection of the nanoantibody according to claim 1 bound to the cells of the cell culture, The detection of the nanoantibody bound to the cells of the cell culture being indicative of infection.

16. In vitro diagnostic method according to the preceding claim characterized in that the previously isolated tissue sample is a sample from the central nervous system.

17. In vitro diagnostic kit comprising the nanoantibody according to claim 1 and means for detecting the specific binding of the nanoantibody to Herpes Simplex virus type 1, Herpes Simplex virus type 2 and / or Varicella Zoster virus.

18. Use of the kit according to the preceding claim to carry out the in vitro diagnostic method according to claim 17.

19. The nanoantibody according to claim 1, the nucleic acid according to claim 2, the vector according to claim 3 or the host cell according to claim 4, or the composition according to any of claims 5 to 8 for use in the treatment of a patient having an infection identified by the in vitro diagnostic method according to claim 15 or with the kit of claim 17.

20. Isolated NBHSV69B nanobody of amino acid sequence SEQ. ID. No.: 3, or isolated protein with an identity of at least 95%, or 99% with SEQ. ID. No.: 3 and possessing the activity and structural characteristics of the NBHSV69B nanobody.

21. Nucleic acid isolated from sequence SEQ. ID. No.: 4 encoding the nanoantibody NBHSV69B according to the preceding claim.

22. Vector comprising the nucleic acid according to the preceding claim.

23. Host cell comprising the nucleic acid according to claim 21 or the vector according to claim 22.

24. Composition comprising the nanoantibody according to claim 20, the nucleic acid according to claim 21, the vector according to claim 22 or the host cell according to claim 23.

25. The composition according to the preceding claim characterized in that it is a pharmaceutical composition.

26. The composition according to the preceding claim, further comprising a pharmaceutically acceptable vehicle and / or pharmaceutically acceptable excipients.

27. The composition according to the preceding claim, further comprising another active ingredient.

28. The nanoantibody according to claim 20, the nucleic acid according to claim 21, the vector according to claim 22 or the host cell according to claim 23, or the composition according to any of claims 24 to 27 for use in the treatment of infection caused by Herpes Simplex Virus type 1.

29. The nanoantibody according to claim 20, the nucleic acid according to claim 21, the vector according to claim 22 or the host cell according to claim 23, or the composition according to any of claims 24 to 27 for use according to claim 28 characterized in that the infection caused by the virus affects the Central Nervous System.

30. The nanoantibody according to claim 20, the nucleic acid according to claim 21, the vector according to claim 22 or the host cell according to claim 23, or the composition according to any of claims 24 to 27 for use in the treatment of herpes encephalitis.

31. The nanoantibody according to claim 20 for use in an in vitro diagnostic method for Herpes Simplex Virus type 1 infection, 32. An in vitro diagnostic method for infection caused by Herpes Simplex virus type 1, performed on a previously isolated tissue sample exhibiting lesions compatible with infection caused by Herpes Simplex virus type 1, comprising: a) infect a cell culture with said isolated sample, b) incubating the infected cell culture together with the nanoantibody according to claim 20, and c) carrying out a test that allows the detection of the nanoantibody according to claim 20 bound to the cells of the cell culture, The detection of the nanoantibody bound to the cells of the cell culture is indicative of infection.

33. In vitro diagnostic method according to the preceding claim, characterized in that the previously isolated tissue sample is a sample from the central nervous system.

34. In vitro diagnostic kit comprising the nanoantibody according to claim 20 and means for detecting the specific binding of the nanoantibody to Herpes Simplex virus type 1.

35. Use of the kit according to the preceding claim to carry out the in vitro diagnostic method according to claim 32.

36. The nanoantibody according to claim 20, the nucleic acid according to claim 21, the vector according to claim 22 or the host cell according to claim 23, or the composition according to any of claims 24 to 27 for use in the treatment of a patient having an infection identified by the in vitro diagnostic method according to claim 32 or with the kit of claim 34.